Anti-viral Sirna Therapy

Simple SummaryContent extracted from patent full text and abstract with AI.

The invention discloses a modified small interfering RNA (siRNA) therapy designed to treat viral infections, in particular those caused by human adenoviruses (hAd). The siRNA molecules are chemically optimized to improve stability, specificity, and reduce off-target effects. These modified siRNAs are encapsulated in lipid nanoparticles for efficient delivery into infected cells, providing an effective means to inhibit viral replication by silencing essential viral genes.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of hepatitis caused by adenovirus infection, especially in immunocompromised patients such as organ transplant recipients or cancer patients undergoing chemotherapy.
• Therapy or prevention of other adenovirus-related diseases, such as respiratory infections, gastroenteritis, conjunctivitis, cystitis, and pharyngitis.
• Protection or treatment of high-risk patient groups, such as pediatric patients or those with immune deficiencies, who are prone to severe adenoviral disease.
• Development of siRNA-based antiviral therapies against other viruses using similar chemical modifications and delivery systems.
• Use in veterinary or agricultural settings to treat viral diseases in animals or plants.

BenefitsContent extracted from patent full text and abstract with AI.

• Increased stability and bioavailability of siRNA in the body, due to chemical modifications and encapsulation in lipid nanoparticles.
• Broader effectiveness against multiple adenoviral subtypes, which can tolerate minor sequence mismatches.
• Significant reduction in viral load and disease severity, as shown in animal models, leading to improved survival and recovery rates.
• Reduced immune activation and lower off-target toxicity compared to traditional siRNA therapies.
• Enables treatment of severe viral infections where no approved therapies currently exist, especially for immunocompromised patients.
• Potential to be administered via various routes (intravenous, subcutaneous, topical, etc.) and adaptable for broad therapeutic needs.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention refers to modified anti-viral siRNA, encapsulated in e.g. lipid nanoparticles (LNP) for treatment of viral infections, and in particular treating infections caused by human adenovirus (hAd).